1. Venture Capital and the Finance of Innovation [Course number] Professor [Name ] [School Name] Chapter 24 R & D Valuation

2. Example: Real Options and Competition Fuelco is considering a consumer application for their patented fuel-cell technology. They have already completed several R&D projects with this technology, so they have eliminated the technical risk for this new project. To begin producing and marketing to the consumer market would require a new investment of $200M, to be paid in one year. The value of Project C depends on consumer demand and also depends on whether a competitor, Cellco, also enters this market. To keep things (relatively) simple, we assume that the beta for the project is zero and that the risk-free rate is also zero, so all discount rates are zero for the both firms. At time 0, Cellco and Fuelco each decide whether to invest or wait. If one firm invests and the other waits, then the investing firm will get the whole market and have an NPV of $300M, whereas the waiting firm will have an NPV of $0. If both firms invest, then competition will drive down the profits of both firms, which will each have an NPV of $50M. If both firms wait, then they both get to observe whether demand is “high” or “low”, after which each firm decides whether or not to invest. If demand is “high” (50 percent chance) and only one firm chooses to invest, then that firm receives an NPV of $700M, and the other firm receives an NPV of $0. If neither firm invests, then both firms receive an NPV of $0. If both firms invest, then each firm receives an NPV of $200M. If demand is “low” (50 percent chance), and only one firm chooses to invest, then that firm receives a negative NPV of –$100M, and the other firm receives an NPV of $0. If neither firm invests, then both firms receive an NPV of $0. If both firms invest, then each firm receives a negative NPV of – $100M.

3. Fuelco’s Project C, with competition

4. Fuelco’s Project C, with competition, pruned

5. Pharmaceutical Alliances  Drugco is about to begin Phase II trials for Newdrug, at a cost of $50M.  If the drug continues to Phase III trials, then these trials would cost an additional $100M.  Bigco, a potential partner, has proposed two possible deal structures.  Deal 1: Up-front payment of $200M, milestone payment of $150M upon entering Phase III, 5 percent royalty on all sales, plus Bigco pays all development costs  Deal 2: Up-front payment of $100M, $300M milestone if Bigco decides to market the product, 10 percent royalties. Drugco absorbs 20 percent of Phase III costs but has decision rights for Phase III continuation.

6. Alliance: Details  Efficacy  Phase II: E’ ~ N(40,40)  Phase III: E ~ N(E’, 20)  Alternative efficacy  Phase II: A’ ~ T(40,70,40)  Phase III: A ~ T(A’, A’+50, A’)  Market size  Phase II: M’ ~ N(1000,50)  Phase III: M ~ N(M’, 100)  Market Share = E 2 / (E 2 + A 2 )  Each dose will sell for $1, with production cost of $0.25.  Discount rate = riskfree rate of 5 percent.  Ten years of patent life would remain after approval.  Marketing costs of $300M in first year, increase with 6 percent market growth rate.

10. Bigco NPV as of Phase III

11. Bigco Zero-Profit Curve, M’ = 1000

12. Bigco Zero-Profit Curves, Deal 1

13. Bigco Zero-Profit Curves, Deal 2